Infant Bacterial Therapeutics Stock Current Valuation
| IBT-B Stock | SEK 59.00 9.00 18.00% |
Valuation analysis of Infant Bacterial helps investors to measure Infant Bacterial's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Infant Bacterial's price fluctuation is not too volatile at this time. Calculation of the real value of Infant Bacterial is based on 3 months time horizon. Increasing Infant Bacterial's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Infant stock is determined by what a typical buyer is willing to pay for full or partial control of Infant Bacterial Therapeutics. Since Infant Bacterial is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Infant Stock. However, Infant Bacterial's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 59.0 | Real 47.2 | Hype 59.0 |
The intrinsic value of Infant Bacterial's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Infant Bacterial's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Infant Bacterial Therapeutics helps investors to forecast how Infant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Infant Bacterial more accurately as focusing exclusively on Infant Bacterial's fundamentals will not take into account other important factors: Infant Bacterial Therapeutics Company Current Valuation Analysis
Infant Bacterial's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Infant Bacterial Current Valuation | 271.56 M |
Most of Infant Bacterial's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infant Bacterial Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Infant Bacterial Therapeutics has a Current Valuation of 271.56 M. This is 98.11% lower than that of the Healthcare sector and 94.15% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 98.37% higher than that of the company.
Infant Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infant Bacterial's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infant Bacterial could also be used in its relative valuation, which is a method of valuing Infant Bacterial by comparing valuation metrics of similar companies.Infant Bacterial is currently under evaluation in current valuation category among its peers.
Infant Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | 271.56 M | |||
| Shares Outstanding | 10.85 M | |||
| Shares Owned By Insiders | 7.23 % | |||
| Shares Owned By Institutions | 33.28 % | |||
| Price To Earning | (18.41) X | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 8,324 X | |||
| Gross Profit | 12 K | |||
| EBITDA | (43.76 M) | |||
| Net Income | (44.99 M) | |||
| Cash And Equivalents | 386.75 M | |||
| Cash Per Share | 48.15 X | |||
| Current Ratio | 109.37 X | |||
| Book Value Per Share | 29.55 X | |||
| Cash Flow From Operations | (55.62 M) | |||
| Earnings Per Share | (5.76) X | |||
| Target Price | 300.0 | |||
| Beta | 1.01 | |||
| Market Capitalization | 560.25 M | |||
| Total Asset | 408.48 M | |||
| Net Asset | 408.48 M |
About Infant Bacterial Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Infant Bacterial Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infant Bacterial using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infant Bacterial Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.